RIGI and neoplasm: The intravesical administration of EG-70 in the bladder, a nanoparticule formulation containing a nanoplasmid encoding both the retinoic acid-inducible gene I (RIG-I) agonist [88] and IL-12, aims at locally inducing a potent immune response in the tumor environment and avoiding systemic toxicities.